Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00291148
Recruitment Status : Completed
First Posted : February 13, 2006
Last Update Posted : July 27, 2012
Information provided by:
University of Manitoba

Brief Summary:
This is a comparative drug trial involving patients with clinically definite Multiple Sclerosis and documented neuropathic pain. Patients will be randomized to receive treatment with either paroxetine or pregabalin. After dose titration, participants will complete various pain scale assessments at several points during the study in order to determine the effectiveness of their assigned pain medication.

Condition or disease Intervention/treatment Phase
Neuropathic Pain Multiple Sclerosis Drug: paroxetine Drug: pregabalin Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Comparative Single Center, Randomized Neuropathic Pain Assessment Study Involving Patients With Clinically Definite Multiple Sclerosis (MS) Receiving Treatment With Either Pregabalin or Paroxetine
Study Start Date : March 2006
Actual Primary Completion Date : July 2012
Actual Study Completion Date : July 2012

Arm Intervention/treatment
Active Comparator: Paroxetine Drug: paroxetine
Active Comparator: pregabalin Drug: pregabalin

Primary Outcome Measures :
  1. Pain levels (as determined by weekly Visual Analogue Scale for pain) [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Short-Form 36 health outcomes survey (SF-36) [ Time Frame: 8 weeks ]
  2. Short-form McGill Pain Questionnaire (SF MPQ) [ Time Frame: 8 weeks ]
  3. Patient-rated Global Impression of Change (PGIC) [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • • Patients presenting with symptoms of neuropathic pain as determined by clinician, with a minimum VAS pain score of 40mm as determined by a baseline score (0mm = no pain, 100mm = worst pain).

    • Male and female patients between the ages of 18 and 65 years old.
    • Clinically definite multiple sclerosis as defined by clinical history review, neurological examination and positive MRI.
    • EDSS scores of < 6.0.
    • No known hypersensitivity to the study medications.
    • Negative serum pregnancy test for all female patients of childbearing age; not currently breastfeeding.
    • Not currently treated with pregabalin, gabapentin, paroxetine or another SSRI.
    • No previous treatment failures with pregabalin or paroxetine.
    • Baseline creatinine clearance (Clcr) of > 50mL/min.
    • No significant hepatic insufficiency.
    • If on other pain medications, must be on stable dose for at least 6 months and other medications must not elicit significant drug-drug interactions with study medications.

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00291148

Layout table for location information
Canada, Manitoba
Multiple Sclerosis Clinic, Health Sciences Centre
Winnipeg, Manitoba, Canada, R3T 2N2
Sponsors and Collaborators
University of Manitoba
Layout table for investigator information
Principal Investigator: Micheal P Namaka, PhD University of Manitoba
Principal Investigator: Dana A Turcotte, BSc Pharm University of Manitoba
Layout table for additonal information Identifier: NCT00291148    
Other Study ID Numbers: MS_B2005:168
First Posted: February 13, 2006    Key Record Dates
Last Update Posted: July 27, 2012
Last Verified: March 2011
Keywords provided by University of Manitoba:
Neuropathic pain
Multiple Sclerosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Neurologic Manifestations
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors